Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

NCT03326336 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-syndromic Retinitis Pigmentosa

Interventions

COMBINATION_PRODUCT: Gene therapy: GS030-DP AND Medical device: GS030-MD

Sponsor

GenSight Biologics